文献速递核素与放射性配体治疗肿瘤 PET/CT

Evans蓝修饰的177Lu-DOTA-EB-TATE治疗转移性神经内分泌肿瘤的剂量递增研究

Dose escalation of an Evans blue-modified radiolabeled somatostatin analog 177Lu-DOTA-EB-TATE in the treatment of metastatic neuroendocrine tumors.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2019-12-12

结果显示EB-TATE组耐受良好,且1.85 GBq和3.7 GBq剂量组疗效优于1.11 GBq组,EB-TATE组SUVmax下降较对照组更显著。

要点

  • 177Lu-DOTA-EB-TATE在1.11–3.7 GBq剂量范围内耐受良好,仅3.7 GBq组2例有化疗史者出现CTC-3血液毒性。
  • 1.85 GBq和3.7 GBq剂量组部分缓解率均为50%,优于1.11 GBq组的0%。
  • EB-TATE组(B–D合并)SUVmax较TATE组显著下降(P=0.045)。

核心结论

  • 177Lu-DOTA-EB-TATE耐受良好且较177Lu-DOTATATE更有效。
  • 1.85 GBq(50 mCi)和3.7 GBq(100 mCi)剂量均较1.11 GBq(30 mCi)剂量更有效。

研究设计与样本

  • 治疗相关不良事件按CTCAE v.5.0分级,基线和治疗后2–3个月行68Ga-DOTATATE PET/CT评估疗效。

主要发现

  • A–C组未观察到CTC 3/4级血液毒性、肾毒性或肝毒性;D组2例既往多疗程化疗患者出现CTC-3级血液毒性。
  • 单周期治疗后,C组SUVmax变化为-17.4±29.3%,D组为-15.1±39.1%,B组为30.0±68.0%,A组为5.4±45.9%。
  • 按EORTC标准,A、B、C、D组部分缓解率分别为16.7%(1/6)、0%(0/7)、50%(3/6)、50%(7/14)。
  • 选取基线SUVmax 15–40的可比病灶,B组SUVmax无显著下降(Δ%=-7.3±24.5%,P=0.214),C组显著下降(Δ%=-34.9±12.4%,P=0.001),D组显著下降(Δ%=-17.9±19.7%,P=0.012),而A组SUVmax升高(Δ%=8.4±48.8%)。
  • EB-TATE组(B–D合并)SUVmax较TATE组显著下降(Δ%=-19.0±21.5%,P=0.045)。

关键数值与推荐

  • 不良事件分级采用CTCAE v.5.0。
  • 疗效评估采用EORTC标准,基线和治疗后2–3个月行68Ga-DOTATATE PET/CT。
  • 分组剂量:A组约3.7 GBq(100 mCi)177Lu-DOTATATE;B组约1.11 GBq(30 mCi)、C组约1.85 GBq(50 mCi)、D组约3.7 GBq(100 mCi)177Lu-DOTA-EB-TATE。

临床怎么用

  • 对于转移性神经内分泌肿瘤,177Lu-DOTA-EB-TATE可考虑在1.85 GBq或3.7 GBq剂量下使用,两者均较1.11 GBq更有效。
  • 治疗前应评估既往化疗史,因有多次化疗史者在3.7 GBq剂量下可能出现CTC-3级血液毒性。

局限性

  • 样本量小,各组例数少(6–14例)。
  • 仅评估单周期治疗后的疗效,需更多周期治疗和更长随访进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To evaluate the safety and efficacy of 177Lu-DOTA-EB-TATE, a radiolabeled somatostatin analog modified by Evans blue, at escalating doses, was used to increase tumor retention in patients with progressive metastatic neuroendocrine tumors (NETs). METHODS: Thirty-three patients with metastatic NETs were prospectively enrolled into four groups: group A (n = 6, 43 ± 12 years) administered approximately 3.7 GBq (100 mCi) 177Lu-DOTATATE as controls; group B (n = 7, 55 ± 7 years) administered approximately 1.11 GBq (30 mCi) 177Lu-DOTA-EB-TATE; group C (n = 6, 55 ± 10 years) administered approximately 1.85 GBq (50 mCi) 177Lu-DOTA-EB-TATE; group D (n = 14, 50 ± 10 years) administered approximately 3.7 GBq (100 mCi) 177Lu-DOTA-EB-TATE. Treatment-related adverse events were graded according to the CTCAE v.5.0. 68Ga-DOTATATE PET/CT were performed at baseline and 2-3 months after treatment for response evaluation. RESULTS: Administration was well tolerated. No CTC 3/4 hematotoxicity, nephrotoxicity, or hepatotoxicity was observed during or after treatment in groups A-C. In group D, CTC-3 hematotoxicity was recorded in 2 patients with multicourse chemotherapy previously. After one-cycle treatment, the SUVmax decreased in group C (Δ% = - 17.4 ± 29.3%) and group D (Δ% = - 15.1 ± 39.1%), but greatly increased in group B (Δ% = 30.0 ± 68.0%) and mildly increased in group A (Δ% = 5.4 ± 45.9%). Referring to EORTC criteria, 16.7% (1/6), 0% (0/7), 50% (3/6), and 50% (7/14) were evaluated as partial response in groups A, B, C, and D, respectively. When selecting lesions with comparable baseline SUVmax ranging from 15 to 40, SUVmax showed no significant decrease in group B (Δ% = - 7.3 ± 24.5%) (P = 0.214), significant decrease in group C (Δ% = - 34.9 ± 12.4%) (P = 0.001), and in group D (Δ% = - 17.9 ± 19.7%) (P = 0.012) as compared with group A with increased SUVmax (Δ% = 8.4 ± 48.8%). SUVmax significantly decreased in the EBTATE groups (groups B-D combined) (Δ% = - 19.0 ± 21.5%) as compared with the TATE group (P = 0.045). CONCLUSION: 177Lu-DOTA-EB-TATE is well tolerated and is more effective than 177Lu-DOTATATE. Both 1.85 GBq (50 mCi) and 3.7 GBq (100 mCi) doses appear to be more effective than 1.11 GBq (30 mCi) dose. Further investigation with more cycles of 177Lu-DOTA-EB-TATE treatment and longer follow-up is warranted. TRIAL REGISTRATION: Treatment Using 177Lu-DOTA-EB-TATE in Patients with Advanced Neuroendocrine Tumors (NCT03478358). URL: https://register.clinicaltrials.gov/prs/app/action/ViewOrUnrelease?uid=U0001JRW&ts=13&sid=S0007RNX&cx=y3yqv4.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Liu Q, Cheng Y, Zang J, et al. Dose escalation of an Evans blue-modified radiolabeled somatostatin analog 177Lu-DOTA-EB-TATE in the treatment of metastatic neuroendocrine tumors. Eur J Nucl Med Mol Imaging. 2019. PMID: 31832728. doi:10.1007/s00259-019-04530-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。